Business · 23/03/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for MYCAMINE Patent Extension
Summary
The Food and Drug Administration has officially set a review period for MYCAMINE, a human drug product, in response to a patent extension application submitted to the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →